Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome

Rituximab may be an effective and safe option as a first-line therapy for inducing and maintaining remission in newly diagnosed INS.

Authors

Siyi He (ORCID: https://orcid.org/0000-0001-7812-997X)
Qiuyu Li (ORCID: https://orcid.org/0000-0003-4007-5536)
Jingjing Wang (ORCID: https://orcid.org/0000-0003-3170-8952)
Xiaojing Zhang (ORCID: https://orcid.org/0000-0002-3217-7105)
Junyi Chen (ORCID: https://orcid.org/0009-0005-1280-2451)
Xue He (ORCID: https://orcid.org/0000-0002-2705-7504)
Guoping Huang (ORCID: https://orcid.org/0000-0002-4081-8398)
Yanyan Jin (ORCID: https://orcid.org/0000-0001-5822-8962)
Haidong Fu
Jianhua Mao (ORCID: https://orcid.org/0000-0002-6076-3806)
Huijun Shen
Yi Xie (ORCID: https://orcid.org/0000-0003-3220-2494)
Fei Liu (ORCID: https://orcid.org/0009-0005-0576-440X)